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Abstract
Background: After viral fusion with the cell membrane, the conical capsid of HIV-1 disassembles by a process
called uncoating. Previously we have utilized the CsA washout assay, in which TRIM-CypA mediated restriction of
viral replication is used to detect the state of the viral capsid, to study the kinetics of HIV-1 uncoating in owl
monkey kidney (OMK) and HeLa cells. Here we have extended this analysis to the human microglial cell lines
CHME3 and C20 to characterize uncoating in a cell type that is a natural target of HIV infection.
Methods: The CsA washout was used to characterize uncoating of wildtype and capsid mutant viruses in CHME3
and C20 cells. Viral fusion assays and nevirapine addition assays were performed to relate the kinetics of viral fusion
and reverse transcription to uncoating.
Results: We found that uncoating initiated within the first hour after viral fusion and was facilitated by reverse
transcription in CHME3 and C20 cells. The capsid mutation A92E did not significantly alter uncoating kinetics.
Viruses with capsid mutations N74D and E45A decreased the rate of uncoating in CHME3 cells, but did not alter
reverse transcription. Interestingly, the second site suppressor capsid mutation R132T was able to rescue the
uncoating kinetics of the E45A mutation, despite having a hyperstable capsid.
Conclusions: These results are most similar to previously observed characteristics of uncoating in HeLa cells and
support the model in which uncoating is initiated by early steps of reverse transcription in the cytoplasm. A
comparison of the uncoating kinetics of CA mutant viruses in OMK and CHME3 cells reveals the importance of
cellular factors in the process of uncoating. The E45A/R132T mutant virus specifically suggests that disrupted
interactions with cellular factors, rather than capsid stability, is responsible for the delayed uncoating kinetics seen
in E45A mutant virus. Future studies aimed at identifying these factors will be important for understanding the
process of uncoating and the development of interventions to disrupt this process.
Keywords: Human immunodeficiency virus, HIV-1, Uncoating, Capsid, CA, Microglia

Background
After fusion of the viral membrane the conical capsid of
HIV is released into the cytoplasm of the cell. This capsid contains approximately 1500 monomers of the viral
capsid protein (CA) arranged in a hexameric lattice
around the viral RNAs and associated proteins [1–3]. In
order for infection to progress this conical capsid
* Correspondence: amyhulme@missouristate.edu
Department of Biomedical Sciences, Missouri State University, Springfield,
MO, USA

structure disassembles by a process called uncoating.
During this time, the viral RNA is reverse transcribed
into a double stranded DNA. The viral complex of nucleic acid and associated proteins also must traffic
through the cytoplasm on microtubules [4–6]. This viral
complex then gains access to the nucleus through a nuclear pore and the viral DNA is integrated into the
chromosomal DNA to establish infection of a cell. Recent evidence suggests that CA and uncoating are at the
crossroads of a complex interplay between these early
steps of HIV replication. Some CA mutations can

© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.

Ingram et al. Virology Journal

(2020) 17:31

disrupt reverse transcription, but blocking reverse transcription also delays uncoating [7–10]. Disruption of protein interactions required for cytoplasmic trafficking
affects the extent of uncoating [11–19]. Finally, determinants for nuclear import and integration site selection
map to the CA protein [20–23], but the viral capsid is too
large to enter the nuclear pore. Some amount of CA protein is proposed to associate with the viral complex after
uncoating to facilitate integration, which has been detected in nuclear viral complexes [24–26]. Therefore, it is
necessary to characterize the process of uncoating in order
to fully understand the early events of HIV replication.
When, where, and how uncoating occurs is an area of
active investigation and source of contention in the field.
Currently there are two models for uncoating [27]. In
the cytoplasmic uncoating model, uncoating occurs in
the cytoplasm as the viral complex is trafficked toward
the nucleus [4, 8, 28–30]. According to the nuclear pore
model, uncoating occurs at the nuclear pore after docking of the intact capsid [31–34]. Distinguishing between
these two models has been challenging due to the overlapping nature of the early steps of HIV replication, differing methods used to assay uncoating, and the
characteristics of defective or noninfectious virions possibly confounding results. Data from studies supporting
both models suggest that a pore opens to destabilize the
capsid integrity and then the hexameric CA lattice disassembles, but the time lag between these events is not
clear [30, 34–38]. These models are also not necessarily
mutually exclusive. A recent hypothesis that draws on
both models proposes that the HIV capsid is destabilized
in the cytoplasm, followed by additional loss of capsid at
the nuclear pore [12, 39].
The primary viral factors involved with uncoating are
the CA protein and the process of reverse transcription.
Mutations in CA can decrease or increase the rate of
uncoating which also decreases HIV infectivity, indicating
that correct timing of uncoating is required for optimal
HIV replication [7, 40–44]. Reverse transcription is also
necessary for uncoating as inhibiting this process delays
uncoating in cultured cell based, biochemical, and microscopy based uncoating assays [8–10, 30, 37, 38, 45]. Specifically, the generation of minus strand strong stop DNA,
an early product of reverse transcription, is proposed to
initiate uncoating [30, 45]. Multiple cellular proteins have
been found to play at least an indirect role in uncoating
[11, 12, 27]. Disruption of the interaction between
eukaryotic translation elongation factor 1A (eEF1A) and
reverse transcriptase delays uncoating, further highlighting
the interplay between reverse transcription and uncoating
[46]. Knockdown of proteins involved with microtubule
trafficking can delay uncoating and impair cytoplasmic
trafficking of viral complexes, including the motor proteins dynein and kinesin-1 Kif5B, kinesin-1 adaptor
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protein FEZ1, microtubule affinity-regulating kinase 2
(MARK2), dynein adaptor protein BICD2, and cytoskeletal
regulatory proteins Dia1 and Dia2 [13–19]. In addition,
knockdown of the nuclear pore protein NUP358 disrupts
cytoplasmic trafficking, nuclear import, and uncoating
[13, 19]. The proteins BICD2, Dia1, Dia2, FEZ1, MARK2,
and NUP358 also have been shown to directly bind to the
capsid to mediate these effects, indicating a direct effect
on uncoating [13–15, 18, 19]. Collectively these results
suggest that uncoating must occur within the correct spatiotemporal context so that the viral complex can interact
with cellular factors for productive HIV infection.
We have previously examined the kinetics of uncoating in owl monkey kidney (OMK) cells and HeLa cells
using the CsA washout assay [8, 40]. This assay utilizes
the activity of the restriction factor TRIM-CypA to bind
to the HIV capsid and then inhibit infectivity [8, 47].
Withdrawal of the drug cyclosporine A (CsA) is used to
activate this TRIM-CypA restriction at various times
post-infection, allowing the kinetics of uncoating to be
revealed. The CsA washout assay is indirect in that relies
on the activity of TRIM-CypA to detect uncoating rather
than directly measuring the level of CA protein. However, fluorescence microscopy based uncoating assays
and biochemical uncoating assays that directly detect the
loss of CA have confirmed a similar timing, effect of reverse transcription, effect of CA mutations, and effect of
cellular factors on uncoating [8–10, 16, 30, 38, 45, 48].
Therefore, while indirect the CsA washout assay provides
a good monitor for the kinetics of successful uncoating in
productively infected cells. An additional strength of the
CsA washout assay is that it provides a direct correlation
between uncoating and infectivity. In order for an uncoating event to be detected, the virus must successfully
uncoat and integrate its DNA into the host cell DNA to
establish productive infection. The majority of HIV virions
that enter cells do not establish productive infection. The
characteristics of these defective virions could bias or obscure results in uncoating studies where a large number of
virions are surveyed without accounting for productive infection [29, 36–38, 48–51].
We previously used the CsA washout assay to examine
the effect of different CA mutations on uncoating in infected
cells [40]. These CA mutations can affect the infection of
nondividing cells, utilization of nuclear import pathways, integration site selection, and interaction with cellular proteins
that facilitate HIV infection [13, 20–23, 48, 52, 53]. We
found that the E45A and N74D mutations uncoated slower
than wildtype virus, while the mutation A92E uncoated faster than wildtype in OMK cells [40]. We also observed differential uncoating kinetics for the mutant N74D in a HeLa
cell line engineered to express TRIM-CypA [40]. These results suggest that cell type differences can impact uncoating
kinetics.
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Given the possible role of cellular environment, here
we have extended our analysis of uncoating to the human microglial cell lines CHME3 and C20 [54, 55].
Microglial cells are natural targets of HIV infection in
humans and serve as a major viral reservoir in the central nervous system [56]. Infection and activation of
microglial cells is proposed to be responsible for AIDS
associated dementia and other neurocognitive defects
observed in some AIDS patients [56]. There has also
been recent interest to use cultured microglial cell
models to study HIV latency [55]. Therefore, it is important to characterize HIV uncoating in this natural
target of HIV infection. Given our previous experiments
in OMK and HeLa cells, we examined the kinetics of
uncoating, role of reverse transcription, and the effect of
different CA mutants on the process of uncoating in
these cultured microglial cell lines.

Material and methods
Cell lines, viruses, and pharmaceuticals

293 T cells were obtained from the American Type Culture Collection and were cultured in Dulbecco’s Modified Eagle Media (Cellgro), 10% fetal bovine serum
(Atlanta Biologicals), and 1% Pen/Strep/Glutamine
(Gibco). CHME3 cell line was a gift M. Naghavi (Northwestern University [54, 57]). The C20 cell line was a gift
from D. Alvarez-Carbonell (Case Western Reserve University [55]). Prior to this study these cell lines were previously established from human microglia [54, 55]. The
stable cell lines CHME3-TC and C20-TC were made
using an HA-tagged TRIM-CypA expressing retroviral
vector (pLXSN-TRIMCypA) to infect CHME3 and C20
cells [58]. Neomycin resistant clonal cell lines (CHME3TC) or hygromycin resistant clonal cell lines (C20-TC)
were screened for TRIM-CypA expression by western
blot against HA and restriction activity. CHME3,
CHME3-TC, C20 and C20-TC cells were cultured in
Dulbecco’s Modified Eagle Media (Cellgro), 5% fetal bovine serum (Atlanta Biologicals), 1% Pen/Strep/Glutamine (Gibco), and 1% sodium pyruvate (Gibco). All cell
lines were maintained at 37 °C and 5% CO2. VSV-g
pseudotyped GFP reporter virus was produced by PEI
transfection of 293 T cells with 6 μg HIV-1 proviral plasmid HIV-GFP or proviral CA mutant plasmid and 4 μg
VSV-g expression plasmid. Virus was harvested 48 h
post-transfection, purified through a 0.45 μm filter, and
stored at − 80 °C until use. Cyclosporine A (Calbiochem)
was prepared in ethanol and used at a final concentration of 2.5 μM. Nevirapine (NIH AIDS Research and
Reference Reagent Program) was prepared in DMSO
and used at a final concentration of 5 μM. Ammonium
chloride was prepared in double-distilled water (ddH2O)
and used at a final concentration of 10 μM.
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CsA washout assay

The CsA washout assay was conducted as previously described [8, 59]. Briefly, CHME3-TC or C20-TC cells
were plated in 96 well dishes at a density of 6000 cells
/well, with each experimental or control reaction performed on triplicate wells. These cells were spinoculated
with VSV-g pseudotyped HIV-GFP or CA mutant virus
in the presence of CsA and 10 μg/ml polybrene for 1 h
at 16 °C. After spinoculation, the inoculation media was
exchanged for warm media, and CsA was washed out of
the zero time point reaction by media exchange. CsA
washout by media exchange continued at various times
post-infection. The negative control for each time point
was ethanol washout by media exchange. To examine
the effect of reverse transcription on uncoating nevirapine was included in the inoculation media and washout
media for the first 2 h of the experiment. After 2 h it
was removed by media exchange on all reactions. Two
days post-infection cells were harvested with 100 μl trypsin and fixed by the addition of 100 μl fix (4:1, 1X PBS:
10% paraformaldehyde). The percentage of GFP positive
cells was determined by flow cytometry using the Accuri
C6 flow cytometer, averaged for each triplicate reaction,
and standard error was calculated. The percentage of infected cells in the ethanol control was subtracted from
the CsA reaction at each washout time point to yield the
percentage of infected cells over background. The data
was normalized by setting the highest percentage of GFP
positive cells to 100% for each virus or condition tested.
The half-life of uncoating was determined by a best fit
line through the two data points flanking 50% uncoating
and times were averaged from multiple independent experiments. For statistical analysis of the half-life of
uncoating, the average half-life of uncoating was compared between the CA mutant virus and its corresponding wildtype CA control using an unpaired T-test.

Viral fusion assay

CHME3-TC and C20-TC cells were plated and spinoculated with HIV-GFP virus as described in the CsA washout assay. When inoculation media was exchanged for
warm media, media containing CsA and the fusion inhibitor ammonium chloride was added to the zero time
point reaction. Ammonium chloride addition continued
by media exchange at various times post-infection. Controls included no treatment and continuous treatment
with ammonium chloride. Two days post-infection, cells
were harvested and the percentage of GFP positive cells
was determined as in the CsA washout assay. The halflife of fusion was determined using a best fit line between the adjacent data points and times were averaged
from five independent experiments. These assay were
conducted in parallel with a CsA washout assay to
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directly compare the half-lives of viral fusion and
uncoating.
Nevirapine addition assay

CHME3-TC cells were plated and spinoculated with
HIV-GFP virus as described in the CsA washout assay.
When inoculation media was exchanged for warm
media, media containing CsA and the reverse transcriptase inhibitor nevirapine (NVP) was added to the zero
time point reaction. NVP addition continued by media
exchange at various times post-infection. Controls included continuous treatment with NVP and DMSO carrier control (no NVP treatment). Two days postinfection, cells were harvested and the percentage of
GFP positive cells was determined as in the CsA washout assay. For each virus, infectivity at each timepoint
was normalized by setting the percentage of infected
cells in the no nevirapine control to 100%. Data from
three independent experiments was averaged for each
virus. For statistical analysis of the progression of reverse
transcription, an unpaired T-test was used to compare
the percentage of GFP positive cells between each CA
mutant virus and the corresponding wildtype CA control
at each timepoint tested.
CsA addition assay

The parent CHME3 cell line used to generate CHME3TC cells was plated as described in the CsA washout
assay. Cells were spinoculated with VSV-g pseudotyped
HIV-GFP in the presence of 10 μg/ml polybrene for 1 h
at 16 °C. When this inoculation media was exchanged
for warm media, media containing CsA or the carrier
control ethanol was added to the zero time point reaction. CsA or ethanol addition continued by media exchange at various times post-infection. Controls
included no treatment and continuous treatment for
both the CsA and ethanol conditions. Cells were harvested and the percentage of GFP positive cells was determined as in the CsA washout assay. The ratio of
infectivity was calculated by dividing the percentage of
GFP positive cells in the CsA reaction by the percentage
of GFP positive cells in the ethanol control reaction for
each time point.

Results
Kinetics of uncoating in microglial cells

To examine the kinetics of uncoating in microglial cells,
we performed the CsA washout assay [8, 47]. In this
assay the HIV restriction factor TRIM-CypA is used to
detect uncoating [60, 61]. To restrict infection multiple
TRIM-CypA proteins assemble in a lattice to bind the
hexameric array of CA protein found in the assembled
HIV-1 capsid [60, 62–64]. Therefore, TRIM-CypA will
bind and inhibit the infectivity of coated viral complexes.
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The drug cyclosporine A (CsA) prevents the binding of
TRIM-CypA to the viral capsid in a reversible fashion
[47, 60, 61, 65]. In the CsA washout assay, cells are synchronously infected with a GFP reporter virus in the
presence of CsA. When CsA is then removed at various
times post-infection, TRIM-CypA can bind to any
coated viral complexes and inhibit infectivity. However,
viral complexes that have progressed through uncoating
such that they are resistant to TRIM-CypA binding and
restriction will still be able to infect the cell. Two days
post-infection cells are harvested and flow cytometry is
used to determine the percentage of infected cells at
each time point. As only uncoated viral complexes can
establish productive infection during TRIM-CypA restriction, this percentage of infected cells correlates to
the percentage of uncoated virions at each timepoint [8].
We engineered the human microglial cell lines
CHME3 and C20 to express TRIM-CypA so that the
CsA washout assay could be used to study uncoating
[54, 55]. The CHME3 cell line, also present in the literature as HMC3, has been verified by a recent study and
the ATCC as a human microglial cell line [57]. The C20
cell line has been more recently established from adult
human cortical microglia and has been characterized as
human microglial by morphology, surface marker expression, RNA expression profile, and sequencing [55].
CHME3 and C20 cells were infected with a retroviral
vector encoding an HA-tagged version of owl monkey
TRIM-CypA. A clonal stable cell line (CHME3-TC or
C20-TC) was established which expressed TRIM-CypA
protein at a sufficient level to restrict HIV replication.
Treatment with the drug cyclosporine A (CsA) was able
to relieve TRIM-CypA restriction in the CHME3-TC and
C20-TC cell lines. To characterize uncoating the CsA
washout assay was performed in CHME3-TC cells and
C20-TC cells using the VSV-g pseudotyped GFP reporter
virus HIV-GFP. In these assays, there was an increase in
the percentage of uncoated viral complexes over time,
which leveled off at 4–5 h post infection (Fig. 1a). In both
cell lines, the majority of uncoating (~ 80%) occurred
within the first 2 h of the experiment. The data were then
normalized by setting the percentage of GFP positive cells
where the curve levels off at 4 or 5 h to 100%, allowing a
half-life of uncoating or time of 50% uncoating to be calculated (Fig. 1a). The average half-life of uncoating was
52.46 min in CHME3-TC cells and 34.95 min in C20-TC
cells (Table 1).
We have previously shown that alterations in the timing of viral fusion can impact the perceived rate of
uncoating in the CsA washout assay [8, 40]. Viral fusion
immediately precedes uncoating and the time for both
viral fusion and uncoating is included in the half-life of
uncoating as calculated above. Therefore, differences in
the rate of viral fusion between CHME3-TC and C20-
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Effect of reverse transcription on uncoating kinetics

To determine the effect of reverse transcription on
uncoating kinetics in microglial cells, we performed the
CsA washout assay using the non-nucleoside reverse
transcriptase inhibitor nevirapine to block reverse transcription for the first 2 h of the assay. This 2 h nevirapine treatment delayed the process of uncoating in
CHME3-TC and C20-TC cells as evidenced by a shift in
the uncoating curve to the right compared to no treatment (Fig. 2). Inhibition of reverse transcription increased in the half-life of uncoating to 137.9 min in
CHME3-TC cells and 136.4 min in C20-TC cells. In
addition, there was a rapid increase in the percentage of
uncoated viral complexes in the first hour after nevirapine removal, between the 2 to 3 h timepoints, in both
cell lines (Fig. 2).

Effect of CA mutations on uncoating

Fig. 1 Kinetics of uncoating and viral fusion in CHME3-TC and C20TC cells. CsA washout assays and viral fusion assays were performed
in parallel to correlate the kinetics of uncoating and viral fusion in
CHME3-TC and C20-TC cells. Shown is a representative experiment
from five independent parallel experiments. Errors bars denote
standard error among triplicate wells. a The uncoating kinetics were
similar in both cell lines with the majority of virus uncoating within
2 h post-infection. b The kinetics of viral fusion were examined by
the addition of ammonium chloride at various times post-infection
to block viral fusion. In both cell lines the majority of virus fused
within 1 h post-infection

TC cells could appear as different uncoating rates. To
directly compare the kinetics of viral fusion and uncoating in both cell lines, we performed a series of viral fusion assays in parallel with CsA washout assays. For the
viral fusion assay cells were spinoculated with HIV-GFP
in the presence of CsA and then ammonium chloride
was added to block VSV-g mediated viral fusion at time
points corresponding to those in CsA washout assay
(Fig. 1b). The average half-life of viral fusion was 43.84
min in CHME3-TC cells and 26.3 min in C20-TC cells
(Table 1). After subtracting the half-life of viral fusion
from the half-life of uncoating, both microglial cell lines
displayed a similar normalized rate of uncoating of 8.6
min (Table 1).

We previously examined the uncoating of a panel of CA
mutant viruses in OMK cells and found that the N74D,
A92E, and E45A mutations altered the rate of uncoating
compared to wildtype [40]. These mutants are of interest
due to their involvement with viral cytoplasmic trafficking, nuclear import, integration, and interaction with cellular factors [13, 20–23, 48, 52, 53]. Therefore, we
examined the effect of these mutations on uncoating in
microglial cells. Using the CsA washout assay, the
uncoating kinetics of each CA mutant was examined in
parallel to the wildtype control HIV-GFP in CHME3-TC
cells. All three mutants decreased the infectivity of HIV.
By normalizing the data for each mutant independently,
this decreased level of infectivity does not bias uncoating
kinetics in the CsA washout assay. Compared to HIVGFP, the N74D mutation delayed the process of uncoating and increased the half-life of uncoating to 141 min
compared to 62 min for wildtype (Fig. 3a). The E45A
mutation also delayed the process of uncoating compared to wildtype, with an average half-life of 102 min
compared to 50 min for wildtype (Fig. 3b). We also examined the uncoating of virus containing the R132T second site suppressor mutation which partially restores the
infectivity of E45A mutant virus [66]. This E45A/R123T
mutant virus uncoated with kinetics like wildtype, with
an average half-life of uncoating of 39 min that was not
statistically different from the average half-life of 43 min
for wildtype in parallel experiments (Fig. 3c). Finally,
A92E mutant virus had an uncoating half-life of 62 min

Table 1 Half-lives of viral fusion and uncoating in CHME3-TC and C20-TC cells
Cell line

Fusion (min)

Uncoating (min)

Normalized uncoating (min)

CHME3-TC

43.84 (SE = 8.02)

52.46 (SE = 8.05)

8.62

C20-TC

26.30 (SE = 1.85)

34.95 (SE = 5.62)

8.65

The average half-lives of viral fusion and uncoating were determined from 5 independent parallel experiments. SE denotes standard error
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that was not statistically different from the 52 min for
wildtype (Fig. 3d).

Effect of CA mutations on reverse transcription

Fig. 2 Effect of reverse transcription on uncoating in CHME3-TC and
C20-TC cells. The effect of reverse transcription on the process of
uncoating in CHME3-TC and C20-TC cells was determined using a 2
h treatment of nevirapine (NVP) in the CsA washout assay.
Treatment with NVP delayed the process of uncoating and increased
the average half-life of uncoating to 137.9 min in CHME3-TC cells
and 136.4 min in C20-TC cells. Shown is a representative experiment
from four independent experiments. Errors bars denote standard
error among triplicate wells

Blocking reverse transcription delays uncoating in
CHME3-TC cells and some CA mutations can disrupt
reverse transcription (Fig. 2 [7]). Therefore, changes in
the uncoating kinetics of the mutant viruses could be
due to alterations in reverse transcription (Fig. 3). To
examine the kinetics of reverse transcription for each
mutant virus, we performed an addition assay with the
non-nucleoside reverse transcriptase inhibitor nevirapine
(NVP; Fig. 4). In this assay, cells were spinoculated with
wildtype or CA mutant GFP reporter virus in the presence of CsA and then NVP was added at time points
corresponding to those in CsA washout assay. At each
timepoint, virus that had completed reverse transcription
would be resistant to nevirapine and able to infect the
cell. The data were normalized by setting the percentage
of GFP positive cells in the DMSO carrier control to

Fig. 3 Effect of CA mutations on uncoating in CHME3-TC cells. The CsA washout assay was performed with CA mutant viruses using HIV-GFP as
the wildtype CA control. Line graphs shown the uncoating kinetics from a representative CsA washout assay. Errors bars denote standard error
among triplicate wells. Bar graphs compare the average half-life of uncoating of CA mutant viruses and the wildtype HIV-GFP control from
multiple independent experiments. Error bars denote standard error among these independent experiments. * indicates a significant difference of
P < 0.05. a The N74D mutation significantly decreased the rate of uncoating among six independent experiments. b The E45A mutation
significantly decreased the rate of uncoating among six independent experiments. c The compensatory mutation R132T was able to rescue the
uncoating kinetics of the E45A mutation to wildtype levels in five independent experiments. d The A92E mutation did not significantly alter the
rate of uncoating among seven independent experiments
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Fig. 4 Reverse transcription kinetics of CA mutant viruses in CHME3TC cells. Completion of reverse transcription was examined using a
nevirapine addition assay. For each virus, infectivity at each
timepoint was normalized to the DMSO carrier control. A statistically
significant difference in reverse transcription compared to the HIVGFP control was not found at any timepoint. Shown is the average
of three independent experiments. Error bars denote standard error
among these independent experiments

100%. Some alterations in completion of reverse transcription were observed, with A92E seeming to reverse
transcribe at the greatest rate and E45A at the slowest
rate (Fig. 4). However, none of these differences were
found to be statistically significant compared to the
HIV-GFP wildtype control at any timepoint. Therefore,
these data suggest that these CA mutations do not affect
completion of reverse transcription at early time points
post-infection in CHME3 cells.

Effect of CsA in CHME3 cells

Cyclosporine A is used in the CsA washout assay to control TRIM-CypA mediated restriction of infection. In
HeLa cells CsA treatment has been shown to decrease
the infectivity of N74D mutant virus, but not virus with
a wildtype capsid [67]. In the CsA washout assay, the
data is normalized for each virus independently, using
the infectivity at 5 or 6 h. However, if there was a differential effect of cyclosporin A on N74D virus over time,
this effect could bias the normalized uncoating kinetics.
Therefore, we examined the effect of CsA on wildtype
and N74D infectivity in the parent CHME3 cell line over
time by performing a CsA washout assay. Treatment
with CsA decreased both wildtype and N74D infectivity
at all time points examined compared to the ethanol
control (Fig. 5). The magnitude of this decrease was determined by calculating ratio of infectivity for each time
point examined (Table 2). In general, the CsA containing
reactions exhibited 63–75% of the infected cells in the
corresponding ethanol control (Table 2). This decrease
was consistent across all time points examined and
within a range of 70–75% during the first 2 h after infection when the majority of uncoating is observed (Fig. 4,
Table 2).

Fig. 5 Effect of CsA on infectivity in CHME3 cells. The effect of CsA
on HIV-GFP and N74D infectivity in the parent CHME3 cell line was
determined by comparing CsA washout and EtOH washout at times
corresponding to the CsA washout assay. The presence of CsA
decreases the infectivity of both HIV-GFP and N74D virus at all time
points tested. Shown is a representative assay from three
independent experiments. Error bars denote standard error among
triplicate wells

Discussion
Here we have characterized HIV uncoating in the microglial cell lines CHME3 and C20. Similar to previous studies in owl monkey kidney (OMK) cells and HeLa cells, the
half-life of uncoating was within an hour post infection
and the majority of virus (~ 80%) uncoated within the first
2 h of infection (Fig. 1 and Table 1 [8, 40]). When comparing the kinetics, uncoating in CHME3 cells had average
half-life of 52.46 min which is intermediate between what
was previously observed in HeLa cells (36.8 min) and
OMK cells (64 min [40]). The average half-life of uncoating in C20 cells was 34.95 min which is similar to the halflife in HeLa cells [40]. As uncoating follows viral fusion,
alterations in the rate of viral fusion in different cell lines
could alter the perceived rate of uncoating. We have
Table 2 Ratio for the effect of CsA on HIV infectivity
Time
(hr)

CsA/EtOH ratio
HIV-GFP

N74D

0

0.72

0.76

0.25

0.63

0.65

0.5

0.68

0.70

0.75

0.70

0.69

1

0.68

0.68

2

0.64

0.68

3

0.70

0.65

4

0.69

0.75

5

0.72

0.73

The magnitude of the effect of CsA was determined by calculating a ratio of
infectivity (%GPP positive cells with CsA treatment/%GPP positive cells in EtOH
carrier control) for each time point examined for HIV-GFP and N74D virus. In
general, the CsA containing reactions exhibited 63–75% of the infected cells in
the corresponding ethanol control
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previously observed this effect when characterizing the
rate of uncoating of VSV-g pseudotyped virus and virus
with wildtype HIV envelope in OMK cells, and the kinetics of uncoating in OMK and HeLa cells [8, 40]. Once the
half-life of viral fusion was subtracted, the uncoating halflife in both CHME3 and C20 cells was 8.6 min (Table 1).
These results suggest that in these microglial cell lines the
uncoating process is initiated fairly early after viral fusion,
within 8 min. These kinetics are most similar to HeLa cells
where the difference in the average half-lives of viral fusion and uncoating was 8 min, while in OMK cells this difference was 45 min [40]. HeLa, CHME3, and C20 cells are
all human cell lines, therefore it is likely they would display more similarities in uncoating compared to OMK
cells.
We do not believe that expression levels of TRIMCypA protein could account for the differences in
uncoating kinetics between CHME3, C20, and OMK
cells. The CsA washout assay was conducted under conditions in which TRIM-CypA restriction was not saturated, meaning that in the absence of CsA viral
infectivity was completely inhibited. TRIM proteins rapidly associate with incoming virus [47]. Under these
non-saturating conditions a sufficient amount TRIMCypA protein was present to bind to the viral capsid and
inhibit infectivity. The presence of additional TRIMCypA protein should not have an additive effect on restriction to alter the detection of coated viral complexes
in the CsA washout assay. A more likely hypothesis is
that differences in the kinetics of uncoating between the
microglial cell lines and OMK cells are due to the presence or absence of cellular factors. Several cellular motor
and trafficking proteins have been identified which affect
HIV uncoating [13–19]. Differential expression or the
differential ability of HIV capsid to interact with owl
monkey cellular factors could account for the overall delayed uncoating kinetics in OMK cells compared to
CHME3 and C20 cells.
The process of reverse transcription has been shown
to have a complicated interplay with the process of
uncoating. Similar to previous studies in OMK cells, inhibition of reverse transcription in CHME3 and C20
cells delayed the process of uncoating in the CsA washout assay (Fig. 2 [8]). This effect of reverse transcription
on uncoating is consistent with multiple studies using a
variety of uncoating assays [8–10, 15, 30, 38, 45]. In
addition, there was a rapid increase in the percentage of
uncoated virions in the first hour after the nevirapine
treatment was removed, indicating that a large number
of viral complexes initiated uncoating after reverse transcription was allowed to proceed (Fig. 2). This result
supports the model where minus strand strong stop
DNA initiates uncoating as this early reverse transcription product could readily be generated in the hour after
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nevirapine removal due to its short length [30, 45]. Our
results also concur with a recent study in which the fate
of the capsid uncoating assay was used to examine the
effect of reverse transcription on uncoating in CHME3
cells [15]. While this was not a kinetic analysis, inhibition of reverse transcription resulted in viral cores with
increased amounts of CA protein at 3 h post-infection,
indicating a delay in uncoating [15].
We next examined the effect of CA mutations on the
process of uncoating. The N74D, E45A, and A92E mutants were chosen because they significantly altered the
rate of uncoating in OMK cells in our previous study [40].
These mutants also can affect the infection of nondividing
cells, utilization of nuclear import pathways, integration
site selection, and interaction with cellular proteins that
facilitate HIV infection [13, 20–23, 48, 52, 53]. Given the
similarities in the kinetics of uncoating and effect of reverse transcription on uncoating in CHME3 and C20 cells,
we tested these mutants only in the CHME3-TC cell line.
N74D and E45A significantly altered the rate of uncoating
compared to the parallel HIV-GFP control in CHME3
cells (Fig. 3). The effect of each mutation on uncoating
was likely more severe than the data indicate because the
CsA washout assay is based on infectivity. An infected cell
in this assay indicates that the virus has successfully uncoated and then established a provirus to express the GFP
reporter. Therefore, the uncoating kinetics of these mutants reveal the extent to which changes in uncoating can
be tolerated while still resulting in productive infection.
Given that changes in the rate of reverse transcription
can affect uncoating we tested progression of reverse transcription in the CA mutants. We found that these mutations did not significantly change the rate of reverse
transcription at early timepoints post-infection in CHME3
cells (Fig. 4 [40]). Therefore, the alterations in uncoating
for E45A and N74D virus were not due to alterations in
reverse transcription. This result is similar to what was
previously found in OMK cells for the E45A, N74D, and
A92E mutations [40]. While some CA mutations have
been shown to have altered capsid stability and changes in
reverse transcription, the capsid mutations in this study
provide a way to uncouple the process of uncoating from
reverse transcription [7]. In previous experiments studying
the effect of reverse transcription on uncoating in OMK
cells, we found that each CA mutant virus had a similar
delay in uncoating in response to nevirapine treatment
[40]. Therefore, the effect of delaying uncoating in the
CsA washout assay was dominant to the effect CA mutations. This result indicates that the contribution of reverse
transcription to uncoating occurs before the effect of the
N74D and E45A capsid mutations. Thus, these data also
support the model by which the minus strand strong stop
DNA initiates uncoating as this product is generated early
in infection.
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While the N74D mutation delayed uncoating in
CHME3 cells, there are differences in the magnitude of
this change compared to our previous studies [40]. In
CHME3 cells N74D mutant virus uncoated with a halflife of 141 min compared to a half-life of 62 min for
wildtype in the parallel assays (Fig. 3a). This ~ 2-fold
change in uncoating kinetics is most similar to results in
HeLa cells, while in OMK cells the N74D mutation only
increased that half-life of uncoating by 50% [40]. This
mutation has also been shown to delay uncoating in
fluorescence microscopy based uncoating assays [30, 35].
The N74D mutation causes HIV to utilize a different nuclear import pathway than that mediated by the
importin-β protein TNPO3, nucleocytoplasmic shuttle
protein CPSF6, and nucleoporin NUP358 [20, 21, 23]. A
study by Dharan et al. showed that knockdown of
NUP358 and the microtubule kinesin-1 motor protein
Kif5B delayed uncoating in HeLa cells using the fluorescence microscopy based in situ uncoating assay [13]. In
this study the N74D mutation also prevented NUP358
and Kif5B from binding to the HIV capsid [13]. Therefore, a likely hypothesis is that the delayed uncoating
kinetics of N74D mutant virus in CHME3 cells is due to
the inability of this mutant to bind Kif5B or NUP358.
The E45A mutation produces a hyperstable capsid lattice with increased stiffness in atomic force microscopy
assays [7, 68]. Like the N74D mutation, this mutation
also results in the use of an alternate nuclear import
pathway than that mediated by TNPO3, CPSF6, and
NUP358 [20, 21]. In the CsA washout assay, the E45A
mutation slowed the rate of uncoating in CHME3 cells
with an increased half-life of 102 min compared to the
wildtype control (Fig. 3b). This result is similar to our
previous study, although there was a more modest delay
in uncoating due to the E45A mutation in OMK cells
[40]. E45A virus was also observed to uncoat slower
than wildtype in fluorescence microscopy based uncoating assays [36, 38]. To determine whether capsid stability
or disrupted interaction with cellular factors was responsible for the delayed uncoating of E45A mutant virus, we
examined the uncoating kinetics of the E45A/R123T
double mutant virus. R132T is a second site suppressor
mutation that was isolated from serial passage of E45A
mutant virus in culture [66]. In this study, the R132T
compensatory mutation partially rescued infectivity and
nuclear import defects of E45A mutant virus [66]. However, E45A/R132T virus still had a hyperstable capsid
[66]. Surprisingly, we found that E45A/R132T virus uncoated with kinetics similar to wildtype (Fig. 3c). Therefore, the delayed uncoating kinetics observed in E45A
virus were not due to a hyperstable capsid. This result
suggests that overall capsid stability may not be a good
predictor of uncoating kinetics, in agreement with other
studies [24, 40, 66, 69]. The E45 and R132 residues are
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distant from each other but are both located near the
NTD-NTD interface. As widespread structural changes
are not observed in E45A or R132T mutant viruses, the
altered chemical natures of these side chains were proposed
to account for the effects of the mutations on replication
[66]. The R132T mutation may restore an interaction surface needed for uncoating, and disruption of this region by
the E45A mutation would result in delayed uncoating. The
E45 residue has not been tested for NUP358 or Kif5B binding like the N74 residue, but mutation at this location may
prevent the association with NUP358, Kif5B, or other
members of the canonical nuclear import pathway that
may be involved with uncoating. Supporting this idea, Yang
et al. showed that the R132T mutation restored the ability
of E45A virus to bind the drug PF74 [66]. PF74 directly
binds to the conical capsid at a site where the cellular factors CPSF6 and the nucleoporin NUP153 bind to mediate
nuclear import [25, 70, 71].
Yang et al. also found that E45A/R132T virus had less
capsid disassembly compared to wildtype in an in vitro
uncoating assay which may seem to contradict our results [66]. In this assay viral capsid cores were purified
from virus, diluted in buffer, and the extent of disassembly after 30 min was assessed by detecting the remaining
intact cores. However, this in vitro uncoating assay did
not expose the capsid to cellular factors which may be
needed for uncoating. In the absence of cellular factors
E45A/R132T virus likely uncoated slower than wildtype
and with a similar efficiency as E45A virus due to its increased capsid stability. In the CsA washout assay E45A/
R132T virus uncoated at a rate that was not significantly
different from wildtype because this assay is performed
in cells which would allow interactions with cellular factors to impact uncoating (Fig. 3).
A92E displayed different behavior than what we have
previously observed. In OMK cells, this mutation increased the rate of uncoating compared to wildtype [40].
However, in CHME3 cells this mutation did not significantly change uncoating kinetics (Fig. 3d). A92E has
been implicated in infection of nondividing cells and altered use the cellular factor cyclophilin A for HIV infection [48, 52, 53]. Given the species difference between
OMK and human cell lines, it is possible that A92E necessitates the use of different cellular factors, thus resulting in a differential effect of this mutation between cell
lines.
Cyclophilin A (CypA) is an abundantly expressed cytoplasmic protein that binds the capsid to alter HIV replication. The exact role of CypA in viral replication is unclear
as it may increase, decrease, or have no effect on infectivity depending on the cell line tested [21, 72–74]. In cells
where cyclophilin A facilitates HIV infection it has been
proposed to play a role in the processes of reverse transcription, uncoating, and nuclear import [21, 72–75].
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CypA was able to modulate uncoating in a cell type
dependent manner in the fate of the capsid assay and
stabilize the capsid in an in vitro uncoating assay [74, 76].
Recently, CypA has been proposed to protect the capsid
from restriction by human TRIM5α in primary human
blood cells [77]. In the CsA washout assay, CsA is used to
prevent binding of TRIM-CypA to the capsid which will
also prevent cellular CypA from binding to the viral capsid. Therefore, observations cannot be made about the effect of CypA on uncoating of wildtype or CA mutant virus
using the CsA washout assay. However, CsA treatment
has been shown to decrease infectivity of N74D virus by
~ 2–3-fold in HeLa cells, whereas wildtype infectivity was
slightly increased [67]. Because the uncoating of each virus
is normalized independently, different sensitivities of wildtype and N74D virus to CsA could impact uncoating kinetics if this sensitivity changes over the time course of the
assay. Therefore, we performed a CsA washout assay in
the parent CHME3 cell line to determine the kinetics of
CsA sensitivity in N74D and wildtype viruses. Compared
to the carrier control ethanol, CsA treatment decreased
the infectivity of both wildtype and N74D mutant virus in
CHME3 cells (Fig. 4). This decrease was greater for wildtype virus compared to N74D mutant virus. However,
these decreases in infectivity were consistently in the
range of 63–75% over the time course of the CsA washout
assay and 70–75% in the first 2 h of the assay for both viruses (Table 2). Therefore, in CHME3 cells sensitivity to
CsA should not bias the uncoating kinetics for wildtype or
N74D virus as determined by the CsA washout assay.
We chose to use the CsA washout assay to study
uncoating as this assay is fairly high throughput compared to other uncoating assays, while allowing the assessment of uncoating kinetics at multiple timepoints
post-infection [27]. In addition, the CsA washout assay
provides a direct correlation between uncoating and successful infection of the cell. As the majority of HIV virions that enter cells do not establish productive
infection, the characteristics of these defective virions
could bias or obscure results. The CsA washout assay is
indirect in that relies on the activity of TRIM-CypA to
detect uncoating. TRIM-CypA self-associates into a hexagonal lattice that binds the hexameric CA lattice, but it
is not known how much of the intact viral capsid must
be present for TRIM-CypA lattice formation and restriction [63, 64]. In the CsA washout assay viral capsids may
uncoat to varying extents in the cytoplasm before exposure to TRIM-CypA binding with the withdrawal of CsA.
However, in a microscopy assay only intact capsids localized to the cytoplasmic bodies of the closely related
TRIM family member rhesus TRIM5α, indicating that
the majority of the capsid lattice may be required for
TRIM protein binding [78]. Therefore, we propose that
in the CsA washout assay TRIM-CypA binds intact
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capsids or viral complexes that have just started to
uncoat. The CsA washout assay would then detect the
initial destabilization of the capsid, an early step of
uncoating. In support of this hypothesis, Mamede et al.
observed uncoating kinetics similar to the CsA washout
assay in live cell imaging assays [30]. In this study,
uncoating was directly monitored by a green fluorescent
protein fluid phase marker that localized to the interior
of the conical capsid. Live cell fluorescence imaging
tracked the loss of this marker at the initiation of
uncoating and also determined which virions resulted in
productive infection of the cell [30]. In addition, multiple
studies using fluorescence microscopy and biochemical
assays that directly detect the loss of CA have revealed a
similar timing, effect of reverse transcription, effect of
CA mutations, and effect of cellular factors on uncoating
as in the CsA washout assay [8–10, 16, 38, 45, 48].
Therefore, while indirect the CsA washout assay provides a good monitor for the kinetics of successful
uncoating in productively infected cells.

Conclusions
In summary, we have characterized uncoating in the human microglial cell lines CHME3 and C20 which are
natural targets of HIV infection. Similar to our previous
results in cell lines that are not natural targets of HIV
infection (OMK and HeLa cells), uncoating initiated
within the first hour of infection and was facilitated by
reverse transcription. These results support the model in
which uncoating is initiated by early steps of reverse
transcription in the cytoplasm and proceeds during
transport of the viral complex to the nucleus. The CA
mutations N74D and E45A delayed HIV uncoating,
while the compensatory mutation R132T was able to
rescue the uncoating kinetics of E45A mutant virus despite still having a hyperstable capsid. Discrepancies between the uncoating kinetics of CA mutant viruses in
OMK and CHME3 cells reveals the importance of cellular factors in the process of uncoating. Specifically, the
E45A/R132T mutant virus suggests that disrupted interactions with cellular factors, rather than capsid stability,
is responsible for the delayed uncoating kinetics seen in
E45A mutant virus. Future studies aimed at identifying
these factors will be important for understanding the
process of uncoating in cells, the influence of uncoating
on other early steps of HIV replication, and the development of interventions to disrupt these processes.
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